



# ClindaMax™ Lotion

(Clindamycin Phosphate Topical Suspension USP, 1%)


FOR EXTERNAL USE ONLY

Rx only

**DESCRIPTION:** ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The topical lotion contains cetostearyl alcohol (2.5%), glycerin, glyceryl stearate SE (with potassium monostearate), isostearyl alcohol (2.5%), methylparaben (0.3%), sodium lauroyl sarcosinate, stearic acid and purified water. The structural formula is represented below:



Molecular Formula: C<sub>18</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>8</sub>PS

Molecular Weight: 504.97

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-*trans*-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-*threo*- $\alpha$ -D-*galacto*-octopyranoside 2-(dihydrogen phosphate).

**CLINICAL PHARMACOLOGY:** Although clindamycin phosphate is inactive *in vitro*, rapid *in vivo* hydrolysis converts this compound to the antibacterially active clindamycin.

Cross resistance has been demonstrated between clindamycin and lincomycin.

Antagonism has been demonstrated between clindamycin and erythromycin.

Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0-3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Clindamycin activity has been demonstrated in comedones from acne patients. The mean concentration of antibiotic activity in extracted comedones after application of Clindamycin Phosphate Topical Solution for 4 weeks was 597 mcg/g of comedonal material (range 0-1490). Clindamycin *in vitro* inhibits all *Propionibacterium acnes* cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.

**INDICATIONS AND USAGE:** ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See **CONTRAINDICATIONS, WARNINGS** and **ADVERSE REACTIONS**.)

**CONTRAINDICATIONS:** ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

**WARNINGS: Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.**

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for *Clostridium difficile* and stool assay for *C. difficile* toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

(OVER)

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by *Clostridium difficile*. The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin *in vitro*. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

**PRECAUTIONS:** **General** - ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) should be prescribed with caution in atopic individuals.

**Drug Interactions:** Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.

**Pregnancy: Teratogenic Effects: Pregnancy Category B:** Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 100 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether clindamycin is excreted in human milk following use of Clindamycin Phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use:** Safety and effectiveness in pediatric patients under the age of 12 have not been established.

**ADVERSE REACTIONS:** In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Treatment Emergent Adverse Event	Number of Patients Reporting Events		
	Solution n= 553 (%)	Gel n= 148 (%)	Lotion n= 160 (%)
Burning	62 (11)	15 (10)	17 (11)
Itching	36 (7)	15 (10)	17 (11)
Burning/Itching	60 (11)	# (-)	# (-)
Dryness	105 (19)	34 (23)	29 (18)
Erythema	86 (16)	10 (7)	22 (14)
Oiliness/Oily Skin	8 (1)	26 (18)	12*(10)
Peeling	61 (11)	# (-)	11 (7)

# not recorded  
\* of 126 subjects

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see **WARNINGS**). Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

**OVERDOSAGE:** Topically applied ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) can be absorbed in sufficient amounts to produce systemic effects. (See **WARNINGS**.)

**DOSAGE AND ADMINISTRATION:** Apply a thin film of ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) twice daily to affected area.

Shake well immediately before using.  
Keep in container and keep tightly closed.

**HOW SUPPLIED:** ClindaMax™ Lotion (Clindamycin Phosphate Topical Suspension USP, 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows:

NDC 0462-0391-60 60 mL bottle

Store at controlled room temperature 15° - 30° C (59° - 86°F).  
Protect from freezing. (See USP)



PharmaDerm  
a division of Altana Inc.,  
Norcross, GA 30093 USA

18391/IF8391  
#43  
R8/02

